Drug & intervention

mannitol

RxCUI 6628

Clinical trials16
Recruiting0
Related conditions15
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Mannitol

Mannitol is a type of sugar alcohol used as a sweetener and medication. It is used as a low-calorie sweetener as it is poorly absorbed by the intestines. As a medication, it is used to decrease pressure in the eyes, as in glaucoma, and to lower increased intracranial pressure. Medically, it is given by injection or inhalation. Effects typically begin within 15 minutes and last up to 8 hours. Common side effects from medical use include electrolyte problems and dehydration. Other serious side effects may include worsening heart failure and kidney problems. It is unclear if use is safe in pregnancy. Mannitol is in the osmotic diuretic family of medications and works by pulling fluid from the brain and eyes. The discovery of mannitol is attributed to Joseph Louis Proust in 1806. It is on the World Health Organization's List of Essential Medicines. It was originally made from the flowering ash and called manna due to its supposed resemblance to the Biblical food. Mannitol is on the World Anti-Doping Agency's banned substances list due to concerns that it may mask prohibited drugs. Mannitol is a natural constituent of most microorganisms and plants, having an essential role in maintaining cell and tissue water balance, and responding to environmental stresses, such as drought or low temperature.

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

16 shown
Coagulation Activation by Hyperosmolar Agents in Intracranial HypertensionNCT03409237 · 2020-12-03
WITHDRAWN
Effect of Intravenous Administration of Mannitol on ONSD in Patients With Raised ICPNCT04188353 · 2019-02-24
COMPLETED
The Effect of Deep Inhalation on Mannitol ResponsivenessNCT03505489 · 2018-06-01
COMPLETED
Effect of Mannitol on Optic Nerve Sheath Diameter in Patients Undergoing Robotic ProstatectomyNCT03214055 · 2017-07-12
COMPLETED
Topical Menthol +/- Mannitol for Painful Diabetic Peripheral NeuropathyNCT02728687 · 2017-03-15
COMPLETED
Asthma Exacerbations and Vascular FunctionNCT02630511 · 2015-12-01
COMPLETED
The Leaky Lung TestNCT02306473 · 2015-10-01
COMPLETED
Change in Airway Responsiveness After Allergen ExposureNCT01699594 · 2012-10-01
COMPLETED
Double Blind Study of Hypertonic Saline vs Mannitol in the Management of Increased Intracranial Pressure (ICP).NCT01108744 · 2012-01-01
WITHDRAWN
Osmotic Therapy for Treatment of Intracranial Hypertension for Traumatic Brain InjuryNCT01215019 · 2010-10-01
WITHDRAWN
Hypertonic Saline vs. Mannitol for Elevated Intercranial PressureNCT01111682 · 2010-04-01
TERMINATED
Mannitol vs HS to Treat ICHT After Severe TBI : Comparison on PtiO2 and Microdialysis ValuesNCT01028339 · 2008-07-01
TERMINATED
Mannitol Bronchoprovocation Challenge Ancillary Study/ACRNNCT00585260 · 2007-12-01
COMPLETED
A Pilot Safety Study of Inhaled Dry Powder Mannitol in Acute Exacerbations of COPDNCT00446667 · 2006-10-01
WITHDRAWN
Effects of Copaxone in the Retinal Function in Diabetic Patients After PanphotocoagulationNCT00677664 · 2006-07-01
UNKNOWN
Cerebral Hemodynamic Effects of Hypertonic Solutions in Severely Head-Injured PatientsNCT00125229 · 2005-08-01
TERMINATED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.